Hemamax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Basile, Lena A ^a   Ellefson, Dolph ^a   Gluzman Poltorak, Zoya ^a   Junes Gill, Katiana ^a   Mar, Vernon ^a   Mendonca, Sarita ^a   Miller, Joseph D ^b   Tom, Jamie ^a   Trinh, Alice ^a   Gallaher, Timothy K ^a  

^a Neumedicines Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; ERYTHROPOIETIN; GAMMA INTERFERON; HEMAMAX; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 15; INTERLEUKIN 18; NEOPTERIN; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL12RB2 PROTEIN, MOUSE; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; RECOMBINANT PROTEIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW; BONE MARROW CELL; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIESIS; HISTOPATHOLOGY; IONIZING RADIATION; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MEGAKARYOBLAST; MOUSE; NEUTROPHIL COUNT; NONHUMAN; OSTEOBLAST; PRIMATE; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION INJURY; RETICULOCYTE COUNT; SINGLE DRUG DOSE; SMALL INTESTINE; STEM CELL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION; WHOLE BODY RADIATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; MACACA MULATTA; MEGAKARYOCYTE; METABOLISM; MONONUCLEAR CELL; TREATMENT OUTCOME;

MACACA MULATTA; MURINAE; MUS; PRIMATES;

ANIMALS; ANTIGENS, CD14; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTESTINE, SMALL; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MALE; MEGAKARYOCYTES; MICE; MICE, INBRED C57BL; OSTEOBLASTS; RADIATION INJURIES, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-12; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84863145540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030434     Document Type: Article

References (82)

1. Drouet M, Herodin F, (2010) Radiation victim management and the haematologist in the future: time to revisit therapeutic guidelines? Int J Radiat Biol 86: 636-648.
2. Donnelly EH, Nemhauser JB, Smith JM, Kazzi ZN, Farfan EB, et al. (2010) Acute radiation syndrome: assessment and management. South Med J 103: 541-546.
3. www.atomicarchive.com Effects of radiation levels on human body. http://www.atomicarchive.com/Effects/radeffectstable.shtml. Accessed June 19, 2011.
4. Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, et al. (2010) Animal models for medical countermeasures to radiation exposure. Radiat Res 173: 557-578.
5. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, et al. (2010) Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 120: 2528-36.
6. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, et al. (2008) An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320: 226-30.
7. Vijay-Kumar M, Aitken JD, Sanders CJ, Frias A, Sloane VM, et al. (2008) Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 180: 8280-5.
8. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, et al. (2010) Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. PLoS One 5: e11056.
9. Singh VK, Yadav VS, (2005) Role of cytokines and growth factors in radioprotection. Exp Mol Pathol 78: 156-69.
10. Hérodin F, Drouet M, (2005) Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp Hematol 33: 1071-80.
11. Weiss JF, Landauer MR, (2009) History and development of radiation-protective agents. Int J Radiat Biol 85: 539-73.
12. Dumont F, Le Roux A, Bischoff P, (2010) Radiation countermeasure agents: an update. Expert Opin Ther Pat 20: 73-101.
13. Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D, (2008) Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 6: 26.
14. Chen T, Burke KA, Zhan Y, Wang X, Shibata D, et al. (2007) IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 35: 203-213.
15. Colombo MP, Trinchieri G, (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168.
16. Jacobsen SE, Veiby OP, Smeland EB, (1993) Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med 178: 413-418.
17. Bellone G, Trinchieri G, (1994) Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 153: 930-937.
18. Ploemacher RE, van Soest PL, Boudewijn A, Neben S, (1993) Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or steel factor. Leukemia 7: 1374-1380.
19. Ploemacher RE, van Soest PL, Voorwinden H, Boudewijn A, (1993) Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture. Leukemia 7: 1381-1388.
20. Hirayama F, Katayama N, Neben S, Donaldson D, Nickbarg EB, et al. (1994) Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture. Blood 83: 92-98.
21. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, et al. (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131: 1300-1305.
22. Gimble JM, Medina K, Hudson J, Robinson M, Kincade PW, (1993) Modulation of lymphohematopoiesis in long-term cultures by gamma interferon: direct and indirect action on lymphoid and stromal cells. Exp Hematol 21: 224-230.
23. Means RT Jr, Krantz SB, (1991) Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 78: 2564-2567.
24. Terrell TG, Green JD, (1993) Comparative pathology of recombinant murine interferon-gamma in mice and recombinant human interferon-gamma in cynomolgus monkeys. Int Rev Exp Pathol 34 Pt B: 73-101.
25. Zoumbos NC, Djeu JY, Young NS, (1984) Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 133: 769-774.
26. Kurz K, Gluhcheva Y, Zvetkova E, Konwalinka G, Fuchs D, (2010) Interferon-gamma-mediated pathways are induced in human CD34(+) haematopoietic stem cells. Immunobiology 215: 452-457.
27. Zhao X, Ren G, Liang L, Ai PZ, Zheng B, et al. (2010) Brief report: interferon-gamma induces expansion of Lin(-)Sca-1(+)C-Kit(+) Cells. Stem Cells 28: 122-126.
28. U.S. Food and Drug Administration. Center for Drug Evaluation and Research (2005) FDA guidance estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Accessed June 13, 2011.
29. Yuan R, Maeda Y, Li W, Lu W, Cook S, et al. (2008) Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 3: e1924.
30. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007.
31. Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, et al. (2010) Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6: 25-36.
32. Garcia MI, Ghiani M, Lefort A, Libert F, Strollo S, et al. (2009) LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev Biol 331: 58-67.
33. Zou JJ, Schoenhaut DS, Carvajal DM, Warrier RR, Presky DH, et al. (1995) Structure-function analysis of the p35 subunit of mouse interleukin 12. J Biol Chem 270: 5864-5871.
34. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, et al. (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 8: 2983-2991.
35. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, et al. (2007) Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5: 66.
36. Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, et al. (2007) Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 110: 4165-4171.
37. Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, et al. (2003) Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 26: 270-276.
38. Neta R, Stiefel SM, Finkelman F, Herrmann S, Ali N, (1994) IL-12 protects bone marrow from and sensitizes intestinal tract to ionizing radiation. J Immunol 153: 4230-4237.
39. Trinchieri G, (1998) Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83-243.
40. Langrish CL, McKenzie BS, Wilson NJ, de Waal MR, Kastelein RA, et al. (2004) IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202: 96-105.
41. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R, (2006) Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin Ter 157: 377-386.
42. Macdougall IC, Cooper AC, (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 (Suppl 11): 39-43.
43. Morceau F, Dicato M, Diederich M, (2009) Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm 2009: 405016.
44. Dinarello CA, Fantuzzi G, (2003) Interleukin-18 and host defense against infection. J Infect Dis 187 (Suppl 2): S370-S384.
45. Gracie JA, Robertson SE, McInnes IB, (2003) Interleukin-18. J Leukoc Biol 73: 213-224.
46. Stonier SW, Schluns KS, (2010) Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 127: 85-92.
47. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H, (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 53-72.
48. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, et al. (1990) Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 265: 3189-3192.
49. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, et al. (1988) Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 9: 150-155.
50. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, et al. (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91: 3974-3978.
51. Brines M, Cerami A, (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6: 484-494.
52. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, et al. (2003) The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 62: 228-236.
53. Fraser JK, Tan AS, Lin FK, Berridge MV, (1989) Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 17: 10-16.
54. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH, (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333.
55. Sela S, Shurtz-Swirski R, Sharon R, Manaster J, Chezar J, et al. (2001) The polymorphonuclear leukocyte-a new target for erythropoietin. Nephron 88: 205-210.
56. Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, et al. (2009) Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol 46: 713-721.
57. Prutchi SS, Lifshitz L, Orkin R, Mittelman M, Neumann D, (2008) Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator? Exp Hematol 36: 1682-1690.
58. Cetin H, Olgar S, Oktem F, Ciris M, Uz E, et al. (2007) Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 34: 1181-1185.
59. Genc S, Akhisaroglu M, Kuralay F, Genc K, (2002) Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 321: 73-76.
60. Kumral A, Gonenc S, Acikgoz O, Sonmez A, Genc K, et al. (2005) Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 87: 15-18.
61. Liu J, Narasimhan P, Song YS, Nishi T, Yu F, et al. (2006) Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress. Glia 53: 360-365.
62. Wang ZY, Shen LJ, Tu L, Hu DN, Liu GY, et al. (2009) Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 46: 1032-1041.
63. Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, et al. (2000) Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58: 269-282.
64. Chong ZZ, Kang JQ, Maiese K, (2002) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106: 2973-2979.
65. Chong ZZ, Kang JQ, Maiese K, (2002) Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22: 503-514.
66. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007.
67. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, et al. (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195: 327-333.
68. Lodoen MB, Lanier LL, (2006) Natural killer cells as an initial defense against pathogens. Curr Opin Immunol 18: 391-398.
69. Varma TK, Lin CY, Toliver-Kinsky TE, Sherwood ER, (2002) Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors. Clin Diagn Lab Immunol 9: 530-543.
70. de Barros AP, Takiya CM, Garzoni LR, Leal-Ferreira ML, Dutra HS, et al. (2010) Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model. PLoS One 5: e9093.
71. Ahmed N, Khokher MA, Hassan HT, (1999) Cytokine-induced expansion of human CD34+ stem/progenitor and CD34+CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts. Stem Cells 17: 92-99.
72. Hamada T, Mohle R, Hesselgesser J, Hoxie J, Nachman RL, et al. (1998) Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 188: 539-548.
73. Hodohara K, Fujii N, Yamamoto N, Kaushansky K, (2000) Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 95: 769-775.
74. Kiel MJ, Morrison SJ, (2006) Maintaining hematopoietic stem cells in the vascular niche. Immunity 25: 862-864.
75. Wang JF, Liu ZY, Groopman JE, (1998) The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 92: 756-764.
76. Dominici M, Rasini V, Bussolari R, Chen X, Hofmann TJ, et al. (2009) Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood 114: 2333-2343.
77. Savino R, Ciliberto G, (2004) A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent. Cell Death Differ 11 (Suppl 1): S2-S4.
78. Zhang S, Wang Q, (2008) Factors determining the formation and release of bioactive IL-12: regulatory mechanisms for IL-12p70 synthesis and inhibition. Biochem Biophys Res Commun 372: 509-512.
79. Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, et al. (2009) Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk Res 33: 1485-1489.
80. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, et al. (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8: 3686-3695.
81. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, et al. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548.
82. Chao NJ, (2007) Accidental or intentional exposure to ionizing radiation: biodosimetry and treatment options. Exp Hematol 35: 24-27.